Skip to main content
OpenTrials
Completed

NCT Number: NCT05143281

The SITE Study - Dexamethasone Ophthalmic Insert In OR on Day of Surgery Versus In-office Post-Op Day 1

To assess the safety and effectiveness of treatment with an intracanalicular dexamethasone (0.4mg) insert in the operating room following cataract surgery/intraocular lens implant (IOL) compared to insertion 1-day post-op.

Completed

Looking for future studies?

Notify Me

Key information

Age range

65 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Grene Vision Group, Wichita, Kansas, United States

Loading trial locations.

About this study

This is a randomized, controlled study to evaluate the safety and effectiveness of treatment with an intracanalicular dexamethasone (0.4mg) insert in the operating room following cataract surgery/intraocular lens implant (IOL) compared to insertion 1-day post-op.

There will be approximately 50 eyes with two groups:

Group 1 (up to 10 eyes) will receive the insert in the lower punctum on the day of surgery in the OR.

Group 2 (up to 40 eyes) will receive the insert in the lower punctum on the day after surgery in the HOPD.

Each subject's participation is expected to last for approximately 1 month and will be required to complete five scheduled visits over the course of the study period: Baseline (Screening Visit), Operative Visit/Insertion Day (Day 0), Day 1, Day 7 and Day 30.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subjects will be eligible for study participation if they:

Are an adult subject aged 65 years or older Are planning to undergo non-complicated CCI CE/PCIOL in one or both eyes Are willing and able to comply with clinic visits and study related procedures Are willing and able to sign the informed consent form

Exclusion criteria

  • Subjects are not eligible for study participation if they:

Have active infectious systemic disease Have active infectious ocular or extraocular disease Have unobstructed nasolacrimal duct in the study eye(s) Have known hypersensitivity to dexamethasone or are a known steroid responder Have a history of ocular inflammation or macular edema Are currently being treated with immunomodulating agents in the study eye(s) Are currently being treated with immunosuppressants and/or oral steroids Are currently being treated with corticosteroid implant (i.e. Ozurdex) Have a history of herpes simplex virus keratitis or present active bacterial, viral, or fungal keratitis in either eye Have a history of complete punctal occlusion in one or both punctum Currently use topical ophthalmic steroid medications Are unwilling or unable to comply with the study protocol Are determined by the Investigator to not be included for reasons not already specified (e.g., systemic, behavioral, or other ocular disease/abnormality) or if the health of the subject or the validity of the study outcomes may be compromised by the subject's enrollment

Treatment and study plan

Dexamethasone 0.4 MG [Dextenza]

Drug

Ophthalmic Intracanalicular Insert

Other names: Dextenza

Primary outcomes

  1. Anterior Chamber Cells

    Time frame: Assessed on Day 7

    As measured by summed ocular inflammation score (0-4 with 4 meaning a worse outcome)

  2. Ocular Pain

    Time frame: Assessed on Day 7

    As measured by ocular pain assessment numerical grading scale (0-10 with 10 meaning a worse outcome)

Secondary outcomes

  1. Mean change in BCVA

    Time frame: Assessed on Day -1, Day 7, Day 30

    As measured by snellen VA

  2. Percentage with complete absence of pain

    Time frame: Assessed on Day -1, Day 1, Day 7, Day 30

    As measured by ocular pain assessment numerical grading scale (0-10 with 10 meaning a worse outcome)

  3. Percentage with complete absence of cell

    Time frame: Assessed on Day -1, Day 1, Day 7, Day 30

    As measured by summed ocular inflammation score (0-4 with 4 meaning a worse outcome)

  4. Physician ease of insertion and visualization

    Time frame: Assessed on Day 1

    As measured by physician questionnaire

Sponsors and collaborators

Lead sponsor

Grene Vision Group

Other

Collaborators

  • Ocular Therapeutix, Inc.

Registry information

Official study title

A Randomized, Controlled Study to Evaluate the Safety and Effectiveness of Treatment With an Intracanalicular Dexamethasone (0.4mg) Ophthalmic Insert in the Operating Room Following Cataract Surgery/Intraocular Lens Implant (IOL) Compared to Insertion 1-day Post-op - The SITE Study

Important dates

Study start
2021
Primary completion
2023
Study completion
2023
First posted
Dec 3, 2021
Registry last updated
Jul 6, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.